Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06228326 · ClinicalTrials.gov registry record · Phase 1

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

A Phase 1 study of Advanced Cancer and Solid Tumor, Adult, sponsored by Krystal Biotech.

Recruiting
Registry status
Phase 1
Development phase
250
Enrollment target
14
Study locations

NCT06228326: Recruiting Phase 1 study of Advanced Cancer and Solid Tumor, Adult, sponsored by Krystal Biotech.

NCT06228326 is a Phase 1 study of Advanced Cancer and Solid Tumor, Adult that is actively recruiting participants, run by Krystal Biotech. The registered enrollment target is 250 participants, roughly in line with the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target. The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06228326, a Phase 1 study of Advanced Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by Krystal Biotech.

RECRUITING
Registry status
Phase 1
Development phase
250 participants
Enrollment target
14
Study locations

Study Summary

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies. This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707. Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase. Combination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks. All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.

Primary Outcome

Percentage of subjects with treatment-related AEs as assessed by NCI-CTCAE v5

Conditions Studied

Advanced Cancer Solid Tumor, Adult Lung Cancer, Non-Small Cell Lung Cancer Metastatic Lung Cancer (NSCLC)

Interventions

  • DRUG Docetaxel
  • DRUG Chemotherapy
  • BIOLOGICAL KB707
  • DRUG Pembrolizumab (KEYTRUDA®)

Study Locations (14)

California

  • Precision NextGen Oncology - Beverly Hills
  • Emad Ibrahim MD Inc - Redlands

Ohio

  • Gabrail Cancer Center Research - Canton
  • Cleveland Clinic - Cleveland

Texas

  • Renovatio Clinical - El Paso
  • Renovatio Clinical - The Woodlands

Alabama

  • XCancer Research Network/Dothan Hematology & Oncology - Dothan

Arizona

  • HonorHealth Research Institute - Scottsdale

Florida

  • BRCR Global - Weston

Indiana

  • IU Simon Comprehensive Cancer Center - Indianapolis

Louisiana

  • Ochsner/MD Anderson Cancer Center - New Orleans

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-04-17
Est. Completion 2028-07
Phase Phase 1
Krystal Biotech

13 total trials

What NCT06228326 shows while recruiting

NCT06228326 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target.

The record links to 5 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.

NCT06228326 lists 14 locations in 11 states (California, Ohio, Texas).

Frequently Asked Questions

What is clinical trial NCT06228326 about?

NCT06228326 is a clinical study titled "A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs". The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebuliz...

What is the current status of trial NCT06228326?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-04-17. Estimated completion is 2028-07.

What conditions does trial NCT06228326 study?

This clinical trial studies the following conditions: Advanced Cancer, Solid Tumor, Adult, Lung Cancer, Non-Small Cell, Lung Cancer Metastatic, Lung Cancer (NSCLC).

What interventions are being tested in trial NCT06228326?

The interventions under investigation include: Docetaxel (DRUG), Chemotherapy (DRUG), KB707 (BIOLOGICAL), Pembrolizumab (KEYTRUDA®) (DRUG).

Who is sponsoring clinical trial NCT06228326?

This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06228326 being conducted?

This trial has 14 study locations across Alabama, Arizona, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06228326's enrollment target sits among peer trials

250 25th of 122 higher than 97 of 122 other Advanced Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06228326

Source: ClinicalTrials.gov NCT06228326, the US trial registry maintained by the National Library of Medicine. NCT06228326 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.